Effect of astragaloside on the apoptosis of human renal carcinoma cell (ACHN) via SDF-1/CXCR4 signaling pathway

doi:10.12092/j.issn.1009-2501.2019.06.010

Abstract

Abstract:

AIM: To observe the effect of astragaloside on the proliferation, apoptosis of human renal carcinoma cell (ACHN) and the activation of SDF-1/CXCR4 signaling pathway. METHODS: ACHN cells were co-cultured with 20, 60 and 120 μmol/L of astragaloside. CCK-8 assay was used to detect the effect of astragaloside on proliferation inhibitory rates of ACHN cells. The apoptotic rates of ACHN cells were analyzed using flow cytometer. Western Blot was used to determine the expression levels of Csapase-8, Bax, Bcl-2, SDF-1 and CXCR4 proteins in ACHN cells. RESULTS:After treatment with 20, 60 and 120 μmol/L of astragaloside, the proliferation inhibitory rates of ACHN cells were significantly increased with time- and dose-dependent manner (P<0.05). The apoptotic rates of ACHN cells in astragaloside groups were significantly increased compared with control group (P<0.05). The expression levels of Csapase-8 and Bax in astragaloside groups were significantly increased, and the expression levels of Bcl-2, SDF-1 and CXCR4 were significantly decreased compared with control group (P<0.05). CONCLUSION: Astragaloside can inhibit the proliferation of ACHN cells and induce the apoptosis of ACHN cells, and its mechanism was associated with the inhibition of SDF-1/CXCR4 cascade.

Key words: astragaloside, human renal carcinoma cell, proliferation, apoptosis

CLC Number:

R736
R965.2

ZOU Zhaoyin, ZHENG Fu, XU Xianshun, DING Wenjuan, CHEN Yan, PU Daojing. Effect of astragaloside on the apoptosis of human renal carcinoma cell (ACHN) via SDF-1/CXCR4 signaling pathway[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 665-669.

References

［1］Cheng SK, Chuah KL. Metastatic renal cell carcinoma to the pancreas: a review［J］. Arch Pathol Lab Med, 2016, 140(6):598-602.
［2］Hes O, Compérat EM, Rioux-Leclercq N. Clear cell papillary renal cell carcinoma, renal angiomyoadenomatous tumor, and renal cell carcinoma with leiomyomatous stroma relationship of 3 types of renal tumors: a review［J］. Ann Diagn Pathol, 2016, 21(11):59-64.
［3］OuYang Y, Huang J, OuYang Z.Enrichment and purification process of astragalosides and their anti-human gastric cancer MKN-74 cell proliferation effect［J］. Afr Health Sci, 2014, 14(1):22-27.
［4］Cheng X, Gu J, Zhang M, et al. Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway［J］. Int Immunopharmacol, 2014, 23(1):304-313.
［5］Jiang K, Lu Q, Li Q, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling［J］. Int Immunopharmacol, 2017, 42(14):195-202.
［6］Teicher BA, Fricker SP. CXCL12(SDF-1)/CXCR4 pathway in cancer［J］.Clin Cancer Res, 2010, 16(11): 2927- 2931.
［7］Qin H, Liu P, Lin S. Effects of Astragaloside IV on the SDF-1/CXCR4 Expression in atherosclerosis of apoE(-/-) mice induced by hyperlipaemia［J］. Evid Based Complement Alternat Med, 2015, 385(11): 154-162.
［8］刘新辉. 黄芪甲苷对高糖诱导肾小管上皮细胞凋亡及线粒体自噬相关蛋白表达的影响［J］. 广州中医药大学学报, 2019, 36(2): 251-255.
［9］Lombardi L, Tavano F, Morelli F, et al. Chemokine receptor CXCR4: role in gastrointestinal cancer［J］. Crit Rev Oncol Hematol, 2013, 88 (3): 696-705.
［10］Wang L, Chen W, Gao L, et al. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma［J］. World J Surg Oncol, 2012, 10(5):212-219.
［11］Rasti A, Abolhasani M, Zanjani LS, et al. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma［J］. J Cancer Res Clin Oncol, 2017, 143(1):95-104.
［12］Guo Q, Wu XH, Lu YP, et al. Relationship between chemokine axis CXCL12- CXCR4 and epithelial ovarian cancer［J］. Chin Med J, 2013, 93(21):1677-1680.
［13］Wu PF, Lu ZP, Cai BB, et al. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer［J］. Chin Med J, 2013, 126(17): 3371-3374.
［14］Ni J, Xie X, Xie J, et al. Role of BCL-2,caspase-3 and NF-κB in astragaloside inducing apoptosis of human NB4 cells［J］. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2014, 22(3):703-706.
［15］Fan Y, Yang F, Cao X, et al. Gab1 regulates SDF-1-induced progression via inhibition of apoptosis pathway induced by PI3K/AKT/Bcl-2/BAX pathway in human chondrosarcoma［J］. Tumour Biol, 2016, 37(1):1141-1149.

[1]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[2]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[3]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[4]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[5]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[6]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[7]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[8]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[9]	HUA Haiyan, YAN Jie, QIN Yufen. Experimental study of schisandrin B attenuates acute myocardial ischemia injury in rats by inhibiting cardiomyocyte apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 848-856.
[10]	DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua. Study on the treatment of thin endometrium with growth hormone and vitamin E [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
[11]	LI Xueheng, LI Long. Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
[12]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[13]	YANG Liu, LUO Ailin, LI Shiyong. Advance of general anesthetics-induced developing brain injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1381-1390.
[14]	TAN Fenglang, REN Hongli, WANG Hongfei. Effect of Phellodendri amurense extract on hippocampal nerve cells induced by Aβ_1-42 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1213-1220.
[15]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.